Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Neutropenia in Myelosuppressed Cancer Patients Treated with Recombinant Human Erythropoietin (EPO)

Daniel G. Wright, MD, Elizabeth C. Wright, PhD MPH, Constance Tom Noguchi, PhD

Blood (2019) 134 (Supplement_1): 1034.

https://doi.org/10.1182/blood-2019-126650

Published: 2019

Journal Articles

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Karen Quillen, MD, Laura M. Dember, MD, John L. Berk, MD, Kathleen T. Finn, RN, Martha Skinner, MD, David C. Seldin, MD, PhD

Blood (2006) 108 (11): 612.

https://doi.org/10.1182/blood.V108.11.612.612

Published: 2006

Journal Articles

Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.

Cynthia A. Kos, MA, Jennifer E. Ward, Karim Malek, MD, Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Carl O’Hara, MD, Lawreen Connors, Ph.D, Martha Skinner, MD, David C. Seldin, MD

Blood (2005) 106 (11): 4078.

https://doi.org/10.1182/blood.V106.11.4078.4078

Published: 2005

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Karen Quillen, MD, Catherine Fisher, RN, Martha Skinner, MD, David C. Sedlin, MD, PhD

Blood (2005) 106 (11): 1160.

https://doi.org/10.1182/blood.V106.11.1160.1160

Published: 2005

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.

Karin I. Weichman, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Michael Rosenzweig, MD, Laura M. Dember, MD, Martha Skinner, MD, Daniel G. Wright, MD, Vaishali Sanchorawala, MD

Blood (2005) 106 (11): 5476.

https://doi.org/10.1182/blood.V106.11.5476.5476

Published: 2005

Journal Articles

Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.

Vaishali Sanchorawala, MD, David C. Seldin, MD, PhD, Daniel G. Wright, MD, Martha Skinner, MD, Kathleen T. Finn, RN, NP, Rodney H. Falk, MD

Blood (2004) 104 (11): 2393.

https://doi.org/10.1182/blood.V104.11.2393.2393

Published: 2004

Journal Articles

Effective Delivery of Antisense Peptide Nucleic Acid Oligomers into Cells by Anthrax "Protective Antigen".

Ying Zhang, PhD, John R. Murphy, PhD, Daniel G. Wright, MD

Blood (2004) 104 (11): 5256.

https://doi.org/10.1182/blood.V104.11.5256.5256

Published: 2004

Journal Articles

Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.

Karen Quillen, MD, Daniel G. Wright, MD, David C. Seldin, MD PhD, Martha Skinner, MD, Karim Malek, MD, Kathleen T. Finn, RN, Vaishali Sanchorawala, MD

Blood (2004) 104 (11): 5226.

https://doi.org/10.1182/blood.V104.11.5226.5226

Published: 2004

Journal Articles

Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

David Cary Seldin, MD, PhD, Jennifer J. Anderson, PhD, Martha Skinner, MD, Karim Malek, MD, Daniel G. Wright, MD, Karen Quillen, MD, Vaishali Sanchorawala, MD

Blood (2004) 104 (11): 923.

https://doi.org/10.1182/blood.V104.11.923.923

Published: 2004

Journal Articles

Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Barbarajean Magnani, MD, PhD, Martha Skinner, MD, David C. Seldin, MD, PhD

Blood (2004) 104 (11): 942.

https://doi.org/10.1182/blood.V104.11.942.942

Published: 2004

NARROW

Neutropenia in Myelosuppressed Cancer Patients Treated with Recombinant Human Erythropoietin (EPO)

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.

High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.

Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.

Effective Delivery of Antisense Peptide Nucleic Acid Oligomers into Cells by Anthrax "Protective Antigen".

Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.

Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only